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There are no established molecular biomarkers for patients with breast cancer receiving 
combination endocrine and CDK4/6 inhibitor (CDK4/6i). We aimed to determine whether 
genomic markers in circulating tumor DNA (ctDNA) can identify patients at higher risk of 
early progression on fulvestrant therapy with or without palbociclib, a CDK4/6i. 
Methods  
PALOMA-3 was a phase III multicenter double-blind randomized controlled trial of palbociclib 
plus fulvestrant (n=347) versus placebo plus fulvestrant (n=174) in patients with endocrine 
pre-treated ER+ breast cancer. Pre-treatment plasma samples from 459 patients were 
analyzed for mutations in 17 genes, copy number in 14 genes, and circulating tumor fraction. 
Progression free survival (PFS) was compared in patients with circulating tumor fraction 
above or below a pre-specified cut off of 10%, and with or without a specific genomic 
alteration. All statistical tests were two-sided. 
Results 
Patients with high ctDNA fraction had worse PFS on both palbociclib plus fulvestrant (HR = 
1.62, 95%CI 1.17–2.24, p=.004) and placebo plus fulvestrant (HR = 1.77, 95%CI 1.21–2.59, 
p=.004.  In multivariable analysis high circulating tumor fraction was associated with worse 
PFS (HR = 1.20 per 10% increase in tumor fraction, 95%CI 1.09–1.32, p<.001, as were 
TP53 mutation (HR = 1.84, 95%CI 1.27– 2.65, p=0.001 and FGFR1 amplification (HR = 






Pre-treatment ctDNA identified a group of high-risk patients with poor clinical outcome 
despite the addition of CDK4/6 inhibition. These patients might benefit from inclusion in 






CDK4/6 inhibitors (CDK4/6i) now play a key role in the treatment of advanced, 
estrogen receptor positive (ER+) breast cancers[1], with established efficacy in combination 
with endocrine therapy in both first and second line treatment[2-8]. However, a substantial 
proportion of patients progress early on treatment and there is a clinical need to identify 
patients at risk of early progression.  
There are a number of established molecular markers associated with poor outcome 
in early ER+ breast cancer, most notably the risk-classifiers based on gene expression 
assessed in tumor biopsies which are now routinely used to augment clinical decision-
making[9]. Genomic markers other than HER2 amplification associated with poorer outcome 
in primary disease include mutations in TP53[10, 11], amplifications in FGFR1[12], which 
may contribute to endocrine therapy resistance[13], and amplification of MYC[14]. Less is 
known of the associations between common genomic aberrations in advanced ER+ breast 
cancer and clinical outcome, particularly in the updated therapeutic landscape that includes 
combination CDK4/6i treatments. 
Recent work has identified a number of potential genomic mechanisms of resistance 
to CDK4/6i, notably amplification of CCNE1, mutations in FAT1, CDK6 over-expression, and 
loss of RB1[15, 16], with emerging data for immune signatures and other oncogenic 
signaling[17, 18]. Of these there are clinical data supporting acquisition of RB1 mutations in 
a minority of cancers progressing on CDK4/6 inhibitors[19, 20], with pre-existing loss of 
functional RB1 associated with poor prognosis on CDK4/6i therapy. Loss of FAT1 was also 
associated with poor outcome on CDK4/6i therapy[21], although inactivating mutations in 
FAT1 are rare in advanced ER+ breast cancer. We have shown previously that mutations in 
PIK3CA and ESR1 in advanced ER+ breast cancer previously treated with endocrine 
therapy, do not predict response to palbociclib[22].   
Circulating tumor DNA (ctDNA) is found in the plasma of a substantial majority of 
patients with advanced cancer, and presents a source of cancer DNA for non-invasive 
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analysis of tumor somatic genetic features. In addition, circulating tumor fraction, the fraction 
of plasma DNA that is derived from the tumor, may be a biological marker that reports both 
on tumor bulk and tumor aggressiveness[23], and is associated with poorer clinical outcome 
in triple negative breast cancer[24]. 
In conducting this analysis we hypothesized that genomic aberrations identified at 
baseline, including mutations, copy number and circulating tumor fraction, could be 
predictive or prognostic of clinical outcome for patients with advanced ER+ breast cancer 
receiving fulvestrant with or without palbociclib, investigating this using a multi-modal ctDNA 
sequencing analysis of plasma DNA from the PALOMA-3 trial.  
 
Methods 
Full details of the methods can be found in the Supplementary Methods. 
Study design and patients 
The design of the PALOMA-3 trial (NCT01942135) and clinical outcome data has 
been previously reported[2]. Patients with advanced, ER+ breast cancer that had previously 
progressed on endocrine therapy were randomized 2:1 to receive palbociclib plus fulvestrant 
or placebo plus fulvestrant.  
Plasma collection and DNA extraction 
Blood was collected in EDTA tubes on day 1 of treatment and within 30 minutes was 
centrifuged at 3000g for 10 minutes before plasma separation. Samples were then stored at 
-80°C prior to DNA extraction. DNA concentration was estimated using a droplet digital PCR 
(ddPCR) assay directed at RPPH1 on the BioRad QX200. 
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Sequencing and digital PCR 
Mutations were assessed in baseline plasma DNA using a previously reported 
targeted error-corrected sequencing approach, utilizing a bespoke bioinformatic pipeline 
incorporating integrated digital error suppression (iDES)[19, 25]. The targeted panel included 
17 genes, with all coding exons of CDK4, CDK6, CDKN1A, CDKN1B, RB1 and NF1, exons 
5-8 of TP53 and mutation hotspots in AKT1, ERBB2, ESR1, PIK3CA, FGFR1, FGFR2, 
FGFR3, KRAS, HRAS and NRAS. Of the baseline plasma DNA sequencing, 195 patients 
were previously sequenced to compare mutational profile with end-of-treatment progression 
plasma[19], with an additional previously unreported 136 patients’ baseline plasma DNA 
sequenced for the comprehensive baseline analysis presented here.   Digital PCR had been 
previously performed on the baseline plasma DNA samples for PIK3CA and ESR1 mutation 
[26]. 
Circulating tumor fraction was assessed using a previously reported bespoke 
targeted amplicon panel including prevalent heterozygous SNPs in 8 regions commonly lost 
in breast cancer, additionally with amplicons assessing for loss or loss of heterozygosity of 
RB1, PTEN and CDKN2A, and for gain of ERBB2, EGFR, PIK3CA, ESR1, CDK4, FGFR1, 
FGFR2, MYC, MCL1, CCND1 and CCNE1[19]. Comparison with tumor fraction estimated 
from low pass whole genome sequencing was performed in 19 samples sequenced with 
tumor fraction estimated using ichorCNA[23]. 
Statistical analysis 
The primary outcome of this study was to identify potential prognostic and predictive 
factors for progression free survival within both treatment arms. PALOMA-3 was designed 
and powered for a clinical endpoint, and as such was not specifically powered for a 
translational analysis. Survival analyses to associate progression-free survival (PFS) with 
genomic aberrations were performed with Cox proportional hazards models, with calculation 
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of hazard ratios, 95% confidence intervals and logrank p values. Proportionality was 
assessed using the method described by Grambsch and Thernau[27]. For circulating tumor 
fraction analysis a 10% cut-off was pre-specified for association with PFS as previously used 
in the literature [23, 24].  To explore the potential statistical significance of genomic 
alterations an initial univariable analysis in each treatment arm was planned, to be followed 
by a multivariable analysis incorporating treatment as a variable to test for interaction. 
Associations of clinical and pathological characteristics with genomic aberrations were 
tested with χ2 tests or Cochran Armitage tests for trend. P values were considered 
statistically significant for values <.05. The Benjamini-Hochberg approach was used to 
adjust for multiple comparisons. All statistical tests were two-sided. 
 
Results 
Circulating tumor fraction and progression free survival 
Of the enrolled patients with available plasma, 401/459 (87.4%) patients had 
sufficient material and subsequent library quality for circulating tumor fraction and copy 
number analysis, a group with outcomes representative of the overall trial population (Figure 
1A, Supplementary figure 1). Circulating tumor fraction assessment was found to agree well 
with orthogonal assessment in a sample of n = 19 plasma samples assessed for tumor 
fraction using low depth whole genome sequencing (Pearson’s r = 0.86, p < .001, 
Supplementary figure 2), and tumor fraction correlated with PIK3CA allele fraction 
(Pearson’s r = 0.71, p < .001, Supplementary figure 3) and TP53 allele fraction (Pearson’s r 
= 0.79, p < .001, Supplementary figure 4).  
A high circulating tumor fraction (>10% fraction, pre-specified) was observed in 
38.9% (156/401), patients (Figure 1B). In the palbociclib plus fulvestrant group median PFS 
in patients with circulating tumor fraction of >10% was 9.2 months (95% CI 5.8-11.1) and for 
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those with circulating tumor fraction ≤10% was 13.6 months (95% CI 11.3-16.6, HR = 1.62, 
95% CI 1.17 – 2.24, logrank p = .004, Figure 1C). In the placebo plus fulvestrant group 
median progression free survival in patients with circulating tumor fraction of >10% was 2.8 
months (95% CI 1.9-3.9) and with circulating tumor fraction ≤10% was 5.5 months (95% CI 
3.7-9.1, HR = 1.77, 95%CI 1.21 – 2.59, logrank p = .004, Figure 1D). In an exploratory 
analysis using discrete cut offs, circulating tumor fractions of >20% were associated with 
increasingly worse PFS (Supplementary Figure 5). 
Genomic analysis in baseline ctDNA and association with clinical characteristics 
Of the 521 patients enrolled in the study, 331/521 (63.5%) had sufficient material and 
subsequent library quality for mutation analysis by sequencing, with this population also 
representative of the overall trial (Figure 1A, Supplementary figure 6). The most commonly 
mutated gene was ESR1 (72/331, 21.8%, Figure 2A and Figure 2B), with a comparable 
prevalence of PIK3CA mutation (55/331, 16.6%) and TP53 (52/331, 15.7%). Smaller 
proportions of patients had mutations in NF1 (21/331, 6.3%), ERBB2 (12/331, 3.6%), and 
AKT1 (10/331, 3.0%). Mutations in ESR1 were polyclonal in a subset of patients (16/72, 
22.2%, Figure 2A).  
Detection of copy number aberrations (CNAs) is technically challenging in samples 
with low circulating tumor fraction, and we assessed the prevalence of CNAs only in the 
group with >10% circulating tumor fraction. The most frequently observed gains from the 
genes included in the panel were MCL1, CCND1, MYC and FGFR1 (Figure 2C) and there 
was evidence of copy number loss and/or loss of heterozygosity (LOH) in similar proportions 
of RB1 (27/156, 17.3%), PTEN (30/156, 19.2%) and CDKN2A (34/156, 22.0%). 
Having established the landscape of genomic aberrations in ctDNA at baseline, we 
assessed associations with clinical characteristics (Figure 2D). A positive association was 
observed between ESR1 mutation and previous endocrine sensitivity (Chi-square p = .015), 
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previous aromatase inhibitor exposure (Chi-square p = .002), bone metastases (Chi-square 
p = .005) and number of all previous lines of treatment for metastatic disease (Cochran 
Armitage p = .019), associations similar to those previously reported using digital PCR 
analysis (Supplementary Figure 7)[22]. Prior aromatase inhibitor therapy (Chi-square q = 
.021) and bone metastases (Chi-square q = .028) remained statistically significant after 
correction for multiple testing using the Benjamini Hochberg method. TP53 mutations were 
positively associated with visceral metastases (Chi-square q = .046), soft tissue/lymph node 
metastases (Chi-square q = .042) and number of disease sites (Cochran Armitage q = .009). 
No other mutations or copy number changes were statistically significantly associated with a 
particular clinical characteristic after correction for multiple testing. There was no a 
detectable association of between circulating tumor fraction >10% and clinical and 
pathological features, after correcting for multiple comparisons (Figure 2D). Mutations in 
specific genes associated with higher circulating tumor fractions in patients - this was 
statistically significant for the most prevalent mutations, in PIK3CA, TP53 and ESR1, most 
likely simply demonstrating that higher circulating tumor fraction means mutation detection in 
ctDNA is more likely (Supplementary figure 8). 
Genomic analysis in baseline ctDNA and progression free survival 
We next analyzed associations between mutations and copy number changes and 
PFS, initially with both treatment groups separately in a univariable analysis. In the group of 
patients treated with palbociclib plus fulvestrant (n = 223 for mutations n = 259 for copy 
number, Figure 3A) TP53 mutations were associated with worse PFS (HR = 2.00, 95% CI 
1.28 – 3.12, logrank p = .002). Multiple  copy number gains were associated with poorer 
PFS including MCL1 gain (HR = 2.29, 95% CI 1.24 – 4.26, logrank q = .014), FGFR1 gain 
(HR 3.40, 95% CI 1.91 – 6.04, logrank q < .001), MYC gain (HR = 2.97, 95% CI 1.67 – 5.26, 
logrank q < .001), CDK4 gain (HR = 4.22, 95% CI 1.33 – 13.41, logrank q = .021) and 
CCNE1 gain (HR = 5.71, 95% CI 2.30 – 14.21, logrank q < .001). Loss and/or LOH of RB1, 
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PTEN and CDKN2A were also associated with worse prognosis (Supplementary figure 9 
and 10).  
In the group of patients treated with placebo plus fulvestrant (n = 108 for mutations 
142 for copy number, Figure 3B), TP53 mutations (HR = 2.26, 95% CI 1.30 – 3.93, logrank q 
= .026) and ESR1 mutations (HR = 1.85, 95% CI 1.13 – 3.02, logrank q = .047) were 
associated with worse PFS after correction for multiple testing using the Benjamini Hochberg 
method.   Copy number gain (amplification) of FGFR1 (HR = 3.61, 95% CI 1.31 – 9.97, 
logrank q = .047) and MCL1 (HR = 2.40, 95% CI 1.15 – 4.99, logrank q = .05) were 
associated with worse PFS. With a 2:1 randomization, the placebo plus fulvestrant group 
was relatively small, making direct comparisons between treatment groups challenging, and 
there were no individual aberrations that had a statistically significant interaction p value with 
treatment.  
With increased circulating tumor fraction is required to detect copy number changes 
in plasma, and higher circulating tumor fraction associates with worse PFS, we performed a 
multivariable survival analysis (Methods and Table 1).  Circulating tumor fraction remained 
statistically significant in the model (HR = 1.20 per 10% increase in tumor fraction, 95%CI 
1.09–1.32, logrank p<.001), along with TP53 mutation (HR = 1.84, 95%CI 1.27– 2.65, 
logrank p=.001) and FGFR1 gain (HR = 2.91, 95%CI 1.61–5.25, logrank p<.001). Patients 
with TP53 mutations and FGFR1 amplifications had a very poor median PFS on palbociclib 
and fulvestrant of 3.7 months and 3.9 months respectively (Figure 4A and 4B).  There was 
no statistically significant interaction for any genomic aberration with treatment 
randomization.  For the analyzed cohort ctDNA analysis identified at least one of the three 
poor prognosis factors, circulating tumor fraction>10%, TP53 mutation or FGFR1 gain in 





Combinations of CDK4/6i and endocrine therapy are standard of care in advanced 
ER+ breast cancer. There are few molecular markers available to identify patients at risk of 
early progression, where increased monitoring to detect progression may be appropriate and 
for whom research efforts might be focused to improve outcomes. We have previously 
published work from the PALOMA-3 trial examining the evolution of resistance[19]. Here we 
build on this by using a multi-modal ctDNA sequencing analysis of all the baseline plasma 
samples to assess for predictive and prognostic genomic features, greatly expanding the 
range of baseline genomic alterations from our previous work on ESR1 and PIK3CA using 
digital PCR[22]. We did not identify any predictive genomic alterations, but circulating tumor 
fraction, TP53 mutation and FGFR1 gain were each independently associated with risk of 
early relapse for both fulvestrant alone and fulvestrant plus palbociclib treatments. 
Approximately half of patients with TP53 mutation or FGFR1 gain detected in plasma DNA 
had progressed by 2 months, despite the addition of a CDK4/6 inhibitor. Combined, these 
genomic markers identify a significant subset of the patients (42.3%), a group who may 
benefit from augmented treatment strategies.  
Broadly, there was strong agreement between the estimated circulating tumor 
fraction and those mutations expected to be commonly clonal, such as in PIK3CA and TP53, 
though the association was weaker at lower mutation allele fractions, likely reflecting 
subclonal mutations and stochastic effects (Supplementary figures 2, 3 and 4). Circulating 
tumor fraction was strongly associated with adverse PFS in both treatment groups in the 
PALOMA-3 study (Figure 1), and emerged as an independent prognostic factor in the 
multivariable analysis - the first demonstration of this association in ER+ breast cancer. 
Although levels of ctDNA are associated with stage and tumor burden[28], they are not 
simply a surrogate for tumor volume and are associated with proliferation[26, 29-32], and it is 
likely that circulating tumor fraction is an independent prognostic marker due to the collective 
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effect of all these elements. Consistent with prior reports, we found no association of ctDNA 
fraction with the number of disease sites. Our findings are also consistent with observations 
in triple negative breast cancer[24], suggesting such analysis could become a general tool in 
stratifying risk for breast cancer patients. In addition, given that circulating tumor fraction is 
associated with the ability to detect genomic aberrations in ctDNA analysis, our analysis 
highlights the importance of considering circulating tumor fraction when validating 
associations between ctDNA detected mutations/copy number changes and clinical 
outcomes. 
We did not identify any genomic alterations that were predictive for outcome on 
palbociclib. In the univariable analysis some alterations were observed to have a consistent 
association with PFS in both arms, notably TP53 and FGFR1 gain (Figure 3) with others 
appearing in only one, such as CCNE1 and CDK4 gain in the palbociclib arm and ESR1 
mutation in the fulvestrant alone arm. However, no statistically significant treatment 
interaction effect was observed with any alteration. Some of these alterations, notably 
CCNE1 gain, which was associated with marked poor prognosis in the palbociclib plus 
fulvestrant group (Figure 3), remain plausible palbociclib resistance markers with prediction 
analysis underpowered due to low prevalence. For prognosis, only TP53 mutation and 
FGFR1 gain remained statistically significantly associated with worse outcome once 
treatment and circulating tumor fraction were taken into account. 
TP53 is one of the most commonly mutated genes in breast cancer[33], observed at 
a higher prevalence in luminal B cancers as compared to luminal A cancers[33]. In this 
analysis TP53 mutations were associated with a distinct clinical phenotype characterized by 
more sites of metastases and more prevalent visceral and soft tissue/LN metastases. TP53 
mutations associate with poorer clinical outcome in ER positive primary breast cancer [10, 
11], and endocrine resistance[34]. Our work suggests that the aggressive biology for TP53 
mutant ER+ breast cancer continues in the advanced setting, with the association between 
 14 
 
TP53 mutation and poor outcome in both treatment arms of the PALOMA-3 trial 
demonstrating consistency of this finding across two different treatments, and raising the 
question of considering this subset of breast cancer a distinct clinical entity.  
FGFR1 amplification emerged as independently associated with early progression. 
FGFR1 amplification is associated with endocrine resistance[13], and with no observed 
interaction effect with treatment, this finding predominantly suggests resistance to the 
fulvestrant backbone element of the combination. As with TP53 mutation a similar effect was 
observed in the separate treatment arms. Nevertheless, recent data has highlighted a 
potential role for FGFR signaling in resistance to CDK4/6i[35]. This suggests the potential of 
FGFR inhibitors, in particular in cancers with high-level FGFR1 amplification[36] that would 
be more readily detectable in ctDNA, to enhance treatment efficacy. However, the FGFR1 
8p11/12 amplicon is often broad, with FGFR1 signaling likely a driver only in a subset of 
cancers[37].  
This report has a number of important limitations. Although we were able to assess 
and account for circulating tumor fraction accurately above 10%, robust assessment of 
tumor fractions below 10% was not possible, and we are unable to ascertain the potential 
impact of lower cut-offs. Calling copy-number is challenging in plasma DNA sequencing, and 
the number of tumors with copy number changes has been under-called; amplifications are 
only detectable in tumors with high tumor fraction or in cancers with lower tumor fractions 
when high levels of copy number are present in the tumor. Genomic loss is even harder to 
assess in plasma DNA, restricted to cancers with the highest tumor purity. Lastly, TP53 
mutations are also found in clonal hematopoiesis[38], and without direct analysis of matching 
buffy coat for the plasma samples we are unable to exclude the effect of this. Prior to 
application in clinical trials, independent validation of these findings will be important.  
In summary, using ctDNA analysis we identify genomic features that associate with a 
risk of early progression on fulvestrant and palbociclib, with at least one feature present in 
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42% of patients in PALOMA-3. Validation of these findings will be required before trials 
assessing clinical utility are conducted [39]. If the observations here can be independently 
validated, then patients with these features may be suitable for clinical trials of more 
intensive surveillance on treatment, or of trials examining escalation of therapy to assess 
these strategies for clinical benefit. 
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Table 1. Multivariable analysis of the association between circulating tumor DNA 
genomic features and progression free survival* 
Variable Hazard ratio (95% CI) P value† 
FGFR1 gain 2.91 (1.61 – 5.25) <.001 
TP53 mutation 1.84 (1.27 – 2.65) .001 
ctDNA tumor 
fraction 
1.20 (1.09 – 1.32) <.001 
Palbociclib 0.43 (0.32 - 0.57) <.001 
*Treatment and circulating tumor fraction are included as variables in the model, the latter as 
a continuous variable calculated per unit 10% increase. P values are logrank. The table 
includes only those factors remaining statistically significant with a p value < .05. The model 
was constructed using forward stepwise selection including all genomic alterations that were 
statistically significant   with logrank p < .05 in either of both of the treatment arms (Figure 3), 
specifically, gain of FGFR1, CCNE1, MCL1, MYC, CDK4, loss of RB1, CDKN2A, PTEN and 





1. Write “Figure 1” in the figure file, “Figure 2”, “Figure 3”, etc. Otherwise the reader 
won’t know what figure they are looking at in the accepted version. 
2. Report all P values using journal style: delete the leading zero; follow the rules on the 
RMC for rounding P values. 
3. All HRs and 95%CIs should have “=” in them (do not use parentheses) and should 
be given to two decimal places. 
Figure 1. Circulating tumor fraction and progression free survival in PALOMA3 
A - CONSORT and Venn diagram showing analysis of plasma samples from the PALOMA-3 
trial. B – Distribution of detected circulating tumor fraction at baseline (n = 401). C – 
Progression free survival for the palbociclib plus fulvestrant group (n = 259) split by 
circulating tumor fraction above or below 10%.D - Progression free survival for the placebo 
plus fulvestrant group (n = 142) split by circulating tumor fraction above or below 10%. P 
values logrank. CI – confidence interval. PFS – progression free survival. 
 
Figure 2. Genomic landscape of endocrine resistant breast cancer in circulating tumor 
DNA analysis.  
A –Distribution and number of mutations by patient at baseline. B – Prevalence of mutated 
genes observed in the baseline plasma samples (n = 331). C – Prevalence of copy number 
gain from the subset of patients with >10% circulating tumor fraction. D - Associations 
between clinic-pathological characteristics and ctDNA genomic features. P values calculated 
with chi squared if categorical or Cochran Armitage tests if ordinal, corrected using 





Figure 3. Association between ctDNA genomic features and progression free survival  
 A – Univariable analyses of progression free survival by detected genomic aberrations for 
the palbociclib plus fulvestrant group. B - Univariable analyses of progression free survival 
by detected genomic aberrations for the placebo plus fulvestrant group. The size of bubble 
indicates the prevalence within the treatment group. P values are logrank. Correction is with 
the Benjamini-Hochberg method.  
 
Figure 4. TP53 mutation, FGFR1 amplification, and progression free survival. 
A - Progression free survival by detected TP53 mutation for the palbociclib plus fulvestrant 
and placebo plus fulvestrant groups. B - Progression free survival by detected FGFR1 gain 
for the palbociclib plus fulvestrant and placebo plus fulvestrant arms. C – Per patient 
distribution of detected TP53 mutation, FGFR1 gain and circulating tumor fraction from the n 
= 310 patients with all of mutations, copy number and circulating tumor fraction data 
available. Hazard ratio univariable analysis, P values logrank. CI – confidence interval. NE – 
not estimable. PFS – progression free survival.  
 22 
 
 
